Drug Trial Radar · NCT07216235
Long-Term Study to Evaluate the Safety and Efficacy in Participants With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes
Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
386
Planned (sponsor's estimate)
Start
Mar 24, 2026
Primary completion
Nov 2032
Study completion Nov 2032
Sponsor
- Lead sponsor
- Zydus Therapeutics Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Long-Term Study to Evaluate the Safety and Efficacy in Participants with Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinical Outcomes (EPICS-V)
Conditions
- Primary Biliary Cholangitis
Interventions
Saroglitazar magnesium 1 mgDrug
Saroglitazar magnesium 1 mg once daily, orally each morning before breakfast
PlaceboDrug
Matching Placebo once daily, orally each morning before breakfast
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the effect of saroglitazar magnesium compared to placebo, based on time to the first occurrence of the defined clinical outcome events in participants with PBC.Time frame: baseline to 48 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Zydus US104
Marietta, Georgia · Recruiting
Zydus US101
Indianapolis, Indiana · Recruiting
Zydus US105
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.